INT218955

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.92
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 3.95
Pain Relevance 3.74

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (ESR1) enzyme binding (ESR1) DNA binding (ESR1)
protein complex (ESR1) cytoplasm (ESR1) signal transduction (ESR1)
Anatomy Link Frequency
a band 1
ESR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
tramadol 121 100.00 Very High Very High Very High
agonist 63 99.50 Very High Very High Very High
Pain 114 99.32 Very High Very High Very High
analgesia 28 98.52 Very High Very High Very High
antagonist 11 97.52 Very High Very High Very High
Chronic low back pain 9 91.16 High High
Opioid 129 90.16 High High
addiction 11 80.96 Quite High
withdrawal 3 77.04 Quite High
Central nervous system 10 73.68 Quite High
Disease Link Frequency Relevance Heat
Pain 171 99.32 Very High Very High Very High
Disorders Of Creatine Metabolism 3 97.60 Very High Very High Very High
Breast Cancer 243 97.20 Very High Very High Very High
Reprotox - General 1 13 92.52 High High
Low Back Pain 14 91.16 High High
Advanced Or Metastatic Breast Cancer 2 90.88 High High
Stress 68 88.44 High High
Apoptosis 63 82.72 Quite High
Death 12 81.20 Quite High
Disease 53 81.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The data were consistent with an enhanced degradation of ER?
Protein_catabolism (degradation) of ER
1) Confidence 0.92 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246173 Disease Relevance 0 Pain Relevance 0
Two hundred and five patients were stabilized on oxymorphone ER with a mean VAS pain intensity rating decrease from 69 at screening to 23 at completion of titration.
Protein_catabolism (stabilized) of oxymorphone ER associated with pain
2) Confidence 0.77 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621383 Disease Relevance 0.95 Pain Relevance 1.64
Tramadol ER vs tramadol IR
Protein_catabolism (Tramadol) of ER associated with tramadol
3) Confidence 0.67 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386353 Disease Relevance 0.66 Pain Relevance 1.67
(Figure 6b) and AR [26,27], induce an increased degradation of ER?
Protein_catabolism (degradation) of ER
4) Confidence 0.61 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246173 Disease Relevance 0.40 Pain Relevance 0.07
It works by both downregulating and degrading the estrogen receptor.
Protein_catabolism (degrading) of estrogen
5) Confidence 0.33 Published 2010 Journal Current Oncology Section Body Doc Link PMC2826783 Disease Relevance 0.32 Pain Relevance 0.18
Alternate forms of directed anti-estrogen therapies do exist for patients with hormone-receptor-positive breast cancer including aromatase inhibitors that block the production of estrogen, and compounds such as fulvestrant (Faslodex®) that down-regulate and degrade the ER protein.
Protein_catabolism (degrade) of ER associated with breast cancer
6) Confidence 0.33 Published 2010 Journal Current Genomics Section Body Doc Link PMC2878980 Disease Relevance 0.58 Pain Relevance 0
The primary function of the UPR is to reduce the accumulation of aberrantly folded proteins in the ER and promote cell survival through a transient decrease in protein translation coupled with increases in the ER's capacity to refold and degrade these proteins[10,11].
Protein_catabolism (degrade) of ER
7) Confidence 0.24 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2527015 Disease Relevance 1.03 Pain Relevance 0
There is also a band at 25 kDa (Figure 4B, Figure 4C), which likely represents a degraded fragment from ER?.
Protein_catabolism (degraded) of ER in a band
8) Confidence 0.17 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2910705 Disease Relevance 0 Pain Relevance 0.09
It might reflect combined effects on receptor synthesis and degradation. 4-MBC exhibits partial agonist features (Schlumpf et al. 2001a), and partial agonists can inhibit proteasomal ER degradation (Fan et al. 2004; Laios et al. 2003), but this should influence also ER-?
Protein_catabolism (degradation) of ER associated with agonist
9) Confidence 0.02 Published 2007 Journal Environ Health Perspect Section Body Doc Link PMC2174398 Disease Relevance 0 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox